GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Terns Pharmaceuticals Inc (STU:430) » Definitions » Investments And Advances

Terns Pharmaceuticals (STU:430) Investments And Advances : €0.00 Mil (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Terns Pharmaceuticals Investments And Advances?

Terns Pharmaceuticals's Investments And Advances for the quarter that ended in Mar. 2025 was €0.00 Mil.


Terns Pharmaceuticals Investments And Advances Historical Data

The historical data trend for Terns Pharmaceuticals's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Terns Pharmaceuticals Investments And Advances Chart

Terns Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Investments And Advances
Get a 7-Day Free Trial - - - - -

Terns Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Terns Pharmaceuticals Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Terns Pharmaceuticals Business Description

Traded in Other Exchanges
Address
1065 East Hillsdale Boulevard, Suite 100, Foster, CA, USA, 94404
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.

Terns Pharmaceuticals Headlines

No Headlines